Ph+ ALL: new approaches for upfront therapy

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is a distinct subtype primarily affecting adults.
• It is characterized by the constitutively active ABL1 kinase, leading to chemotherapy resistance and poor prognosis.
• Historically, outcomes were dismal, especially without allogeneic hematopoietic stem cell transplantation (alloHCT) in first complete remission (CR).

Purpose of the Study:

• To review recent advancements in the initial treatment of adult Ph+ ALL.
• To discuss future directions in managing this challenging leukemia subtype.
• To highlight the impact of novel therapeutic and diagnostic tools.

Main Methods:

• Review of recent advancements in Ph+ ALL treatment.
• Analysis of improved understanding of Ph+ ALL biology.
• Evaluation of new therapeutic and diagnostic tools.

Main Results:

• Imatinib, the first tyrosine kinase inhibitor (TKI), transformed Ph+ ALL treatment, improving CR rates and alloHCT eligibility.
• Recent progress includes more potent TKIs targeting resistance mutations, refined chemotherapy and alloHCT regimens, immunotherapy (blinatumomab), and improved measurable residual disease (MRD) monitoring.
• Recognition of distinct Ph+ ALL subtypes (multilineage and lymphoblast-only) aids in understanding disease biology.

Conclusions:

• The treatment landscape for Ph+ ALL has dramatically improved due to targeted therapies and immunotherapy.
• Advances in diagnostics, including MRD monitoring, enhance patient management.
• Future directions focus on optimizing combination therapies and understanding disease heterogeneity for better adult Ph+ ALL outcomes.